Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-GEMOX plus immunotherapy and targeted therapy for intrahepatic cholangiocarcinoma with lymph node metastases
ChiCTR2500115183Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: 1-year overall survival and 2-year overall survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500115183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115183.